• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

The effects of cilostazol on the monoamine transporter, which is known as cellular target of antidepressants

Research Project

Project/Area Number 16K16456
Research Category

Grant-in-Aid for Young Scientists (B)

Allocation TypeMulti-year Fund
Research Field Rehabilitation science/Welfare engineering
Research InstitutionUniversity of Occupational and Environmental Health, Japan

Principal Investigator

Itoh Hideaki  産業医科大学, 医学部, 助教 (30609201)

Project Period (FY) 2016-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywordsシロスタゾール / 抗血小板薬 / 脳卒中後うつ / 遷延性気分障害 / ノルエピネフリントランスポーター / セロトニントランスポーター / アパシー / 抗うつ作用 / 行動実験 / 脳梗塞後遷延性気分障害 / モノアミントランスポーター / リハビリ進行
Outline of Final Research Achievements

Introduction: The antidepressive effects of cilostazol on post-stroke depression have been reported, but the exact mechanism of this action is unknown.The aim of this study was to investigate the direct effects of cilostazol on NET and SERT function.Methods: SK-N-SH and SERT-transfected COS-7 cells were incubated with [3H]norepinephrine (NE) or [3H]serotonin (5-HT) in the presence or absence of cilostazol to assess the monoamine uptake.Results: Cilostazol decreased the [3H]NE uptake by SK-N-SH cells and the [3H]5-HT uptake by SERT-transfected COS-7 cells in a concentration-dependent manner.Conclusions: The blood concentration of cilostazol in treating patients with cerebrovascular disease has been reported to be 13.8 M after a single oral dose of 100 mg. These results indicate that cilostazol inhibit NET and SERT function at clinically relevant concentration, which is likely to show the antidepressant effect on post-stroke depression.

Academic Significance and Societal Importance of the Research Achievements

脳卒中後の遷延性気分障害はリハビリテーション実施の大きな阻害要因になる。今回、培養細胞において抗血小板薬であるシロスタゾールが抗うつ薬と類似したやや弱い作用を持つことが示唆されたことは,シロスタゾールがアパシーやうつ症状などの遷延性気分障害の改善に寄与する可能性が示唆され,今後脳梗塞後の再発予防として投与される抗血小板薬の選択に影響を及ぼす可能性が考えられる。

Report

(5 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (10 results)

All 2019 2018 2017 2016

All Presentation (10 results) (of which Int'l Joint Research: 5 results,  Invited: 1 results)

  • [Presentation] 抗血小板薬・シロスタゾールがモノアミン機能に及ぼす影響2019

    • Author(s)
      伊藤英明、佐伯覚
    • Organizer
      第4回黒潮カンファレンス
    • Related Report
      2019 Annual Research Report
  • [Presentation] The effects of cilostazol on the monoamine transporter, which is known as cellular target of antidepressants2018

    • Author(s)
      伊藤英明
    • Organizer
      26rd European Congress of Psychiatry
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Cilostazol shows the possibility of effect for post-stroke depression and apathy2018

    • Author(s)
      伊藤英明
    • Organizer
      12th World Congress of the International Society of Physical and Rehabilitation Medicine (ISPRM)
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] 抗血小板薬シロスタゾールはモノアミントラするンスポーター機能を抑制する2017

    • Author(s)
      伊藤英明、豊平由美子、柳原延章、佐伯 覚
    • Organizer
      第46回 日本心脈管作動物質学会
    • Place of Presentation
      琉球大学医学部 臨床講義棟(沖縄県・宜野湾市)
    • Year and Date
      2017-02-10
    • Related Report
      2016 Research-status Report
  • [Presentation] Cilostazol shows the possibility of antidepressant effects on post-stroke depression2017

    • Author(s)
      伊藤英明、豊平由美子、松嶋康之、柳原延章、佐伯 覚
    • Organizer
      3rd European Stroke Organization Conference
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] 抗血小板薬シロスタゾールによる抗うつ作用とモノアミントランポーターとの関連2017

    • Author(s)
      伊藤英明、佐伯 覚
    • Organizer
      第54回 日本リハビリテーション医学会
    • Related Report
      2017 Research-status Report
  • [Presentation] The effects of cilostazol on the monoamine transporter, which is known as cellular target of antidepressants2017

    • Author(s)
      伊藤英明、豊平由美子、松嶋康之、佐伯 覚
    • Organizer
      26rd European Congress of Psychiatry
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Presentation] Cilostazol decreases the function of norepinephrine transporter and serotonin transporter, which is known as cellular target of antidepressants.2016

    • Author(s)
      Hideaki Itoh、Yumiko Toyohira、Yasuyuki Matsushima、Nobuyuki Yanagihara、Satoru Saeki
    • Organizer
      10th World Congress of the International Society of Physical and Rehabilitation Medicine
    • Place of Presentation
      Kuala Lumpur Convention Center(クアラルンプール・マレーシア)
    • Year and Date
      2016-05-29
    • Related Report
      2016 Research-status Report
    • Int'l Joint Research
  • [Presentation] 抗うつ薬の標的蛋白であるモノアミントランスポーターに対する抗血小板薬・シロスタゾールおよび脳代謝改善薬・ニセルゴリンの作用2016

    • Author(s)
      伊藤英明、松嶋康之、佐伯 覚
    • Organizer
      第53回日本リハビリテーション医学会
    • Place of Presentation
      国立京都国際会館グランドプリンスホテル京都(京都府・京都市)
    • Related Report
      2016 Research-status Report
  • [Presentation] 脳代謝改善薬および抗血小板薬が抗うつ薬の標的であるモノアミントランスポーターに及ぼす効果2016

    • Author(s)
      伊藤英明
    • Organizer
      第11回日本リハビリテーション医学会 専門医会 学術集会
    • Place of Presentation
      金沢市文化ホール(石川県・金沢市)
    • Related Report
      2016 Research-status Report
    • Invited

URL: 

Published: 2016-04-21   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi